Biodesix Inc (BDSX)vsIQVIA Holdings Inc (IQV)
BDSX
Biodesix Inc
$28.43
-2.64%
HEALTHCARE · Cap: $284.51M
IQV
IQVIA Holdings Inc
$269.88
+1.30%
HEALTHCARE · Cap: $43.85B
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 16398% more annual revenue ($16.98B vs $102.94M). IQV leads profitability with a 8.1% profit margin vs -27.0%. IQV earns a higher WallStSmart Score of 55/100 (C).
BDSX
Avoid29
out of 100
Grade: F
IQV
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-8.5%
Fair Value
$9.54
Current Price
$28.43
$18.89 premium
Margin of Safety
+12.0%
Fair Value
$201.30
Current Price
$269.88
$68.58 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 34.2% year-over-year
Every $100 of equity generates 22 in profit
Growing faster than its price suggests
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 32.7x book value
ROE of -349.9% — below average capital efficiency
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 0.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : BDSX
The strongest argument for BDSX centers on Revenue Growth. Revenue growth of 34.2% demonstrates continued momentum.
Bull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bear Case : BDSX
The primary concerns for BDSX are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 7.85 is elevated, increasing financial risk.
Bear Case : IQV
The primary concerns for IQV are P/E Ratio, Piotroski F-Score, EPS Growth. Debt-to-equity of 2.63 is elevated, increasing financial risk.
Key Dynamics to Monitor
BDSX profiles as a hypergrowth stock while IQV is a value play — different risk/reward profiles.
IQV carries more volatility with a beta of 1.19 — expect wider price swings.
BDSX is growing revenue faster at 34.2% — sustainability is the question.
IQV generates stronger free cash flow (360M), providing more financial flexibility.
Bottom Line
IQV scores higher overall (55/100 vs 29/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biodesix Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?